Allogene Therapeutics ALLO Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $40.6M-34.5% | $61.98M+28.8% | $48.11M-23.2% | $62.62M+18.7% | $52.75M-38.3% | ||
| $236.58M+19.2% | $198.52M-7.4% | $214.38M-2.9% | $220.79M-7.1% | $237.59M+9.4% | ||
| $273.29M+6.0% | $257.75M-1.1% | $260.72M-7.8% | $282.66M-3.1% | $291.58M-3.9% | ||
| $70.02M-3.9% | $72.84M-4.0% | $75.9M-3.8% | $78.86M-5.0% | $82.99M-3.6% | ||
| $395.96M-4.8% | $415.91M-5.4% | $439.77M-6.5% | $470.59M-7.4% | $507.98M-7.4% | ||
| $4.93M+15.5% | $4.27M+15.4% | $3.7M-23.7% | $4.85M-4.1% | $5.06M-6.2% | ||
| $28.33M-12.9% | $32.51M+2.1% | $31.83M+0.5% | $31.68M+5.5% | $30.02M-15.5% | ||
| $117.08M-5.1% | $123.36M-0.9% | $124.44M-1.3% | $126.03M+2.8% | $122.59M-3.1% | ||
| 400M0.0% | 400M0.0% | 400M0.0% | 400M0.0% | 400M+188,579% | ||
| -$2.05B-2.1% | -$2.01B-2.0% | -$1.97B-2.1% | -$1.93B-2.7% | -$1.88B-3.3% | ||
| $278.88M-4.7% | $292.54M-7.2% | $315.33M-8.5% | $344.56M-10.6% | $385.39M-8.7% | ||
| $395.96M-4.8% | $415.91M-5.4% | $439.77M-6.5% | $470.59M-7.4% | $507.98M-7.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Allogene Therapeutics's total assets?
- Allogene Therapeutics (ALLO) holds $396.0M in total assets, down 22.1% year over year.
- How much debt does Allogene Therapeutics have?
- Allogene Therapeutics carries $81.1M in total debt against $278.9M of shareholders' equity, a debt-to-equity ratio of 0.29.
- How much cash does Allogene Therapeutics have?
- Allogene Therapeutics holds $40.6M in cash and equivalents.
- Can Allogene Therapeutics cover its short-term obligations?
- Its current ratio is 9.65 — current assets exceed current liabilities.
- Where does Allogene Therapeutics's balance sheet data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.